DHEA AND KETOCONAZOLE

DHEA 和酮康唑

• 批准号: 7378779
• 负责人: JOSEPH A EUSTACE
• 金额: $ 0.11万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378779
• 关键词: DHEA; KETOCONAZOLE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study has 2 components. Phase 1 identifies patients who have progressive chronic kidney disease despite optimal conservative management including the use of adequate blood pressure control and a low protein, amino acid supplemented diet. In phase 2 those patients with a progressive decrease in kidney function despite these measures are treated with 200 mg/day of ketoconazole plus low dose prednisone (2.5 mg/day). Currently two patients with insulin-dependent diabetes mellitus and nephropathy continue to receive ketoconazole plus prednisone and maintain independent renal function. Six patients continue to be followed in phase 1 of the study and continue to show stable renal function. Three additional new patients were entered into Phase 1. One had very advanced kidney failure at the time of initial assessment and rapidly progressed to dialysis. The other two are currently being followed to assess the degree of progression of their kidney failure.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这项研究有两个组成部分。1期试验确定了进行性慢性肾病患者，尽管采用了最佳保守治疗，包括适当的血压控制和低蛋白、氨基酸补充饮食。在2期，尽管采取了这些措施，但肾功能仍进行性下降的患者接受200 mg/天的酮康唑加低剂量强的松（2.5 mg/天）治疗。目前2例胰岛素依赖型糖尿病肾病患者继续接受酮康唑加强的松治疗，维持独立肾功能。6名患者在1期研究中继续随访，并继续表现出稳定的肾功能。另外三名新患者进入了第一阶段。一名患者在初步评估时肾衰竭非常严重，并迅速发展到透析。另外两名患者目前正在接受随访，以评估其肾衰竭的进展程度。